A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Identifieur interne : 000C96 ( PubMed/Corpus ); précédent : 000C95; suivant : 000C97A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Auteurs : Walter Wodal ; Falko G. Falkner ; Astrid Kerschbaum ; Claudia Gaiswinkler ; Richard Fritz ; Stefan Kiermayr ; Daniel Portsmouth ; Helga Savidis-Dacho ; Sogue Coulibaly ; Christina Piskernik ; Christine Hohenadl ; M Keith Howard ; Otfried Kistner ; P Noel Barrett ; Thomas R. KreilSource :
- Vaccine [ 1873-2518 ] ; 2012.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Dose-Response Relationship, Immunologic, Female, Guinea Pigs, Hemagglutination Inhibition Tests, Hemagglutinin Glycoproteins, Influenza Virus (immunology), Influenza A Virus, H9N2 Subtype (immunology), Influenza Vaccines (immunology), Lung (pathology), Lung (virology), Mice, Mice, Inbred BALB C, Neuraminidase (immunology), Neutralization Tests, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Weight Loss.
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase.
- immunology : Influenza A Virus, H9N2 Subtype, Orthomyxoviridae Infections.
- pathology : Lung.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung.
- Animals, Dose-Response Relationship, Immunologic, Female, Guinea Pigs, Hemagglutination Inhibition Tests, Mice, Mice, Inbred BALB C, Neutralization Tests, Weight Loss.
Abstract
Influenza viruses of subtype A/H9N2 are enzootic in poultry across Asia and the Middle East and are considered to have pandemic potential. The development of new vaccine manufacturing technologies is a cornerstone of influenza pandemic preparedness.
DOI: 10.1016/j.vaccine.2012.04.102
PubMed: 22580355
Links to Exploration step
pubmed:22580355Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.</title><author><name sortKey="Wodal, Walter" sort="Wodal, Walter" uniqKey="Wodal W" first="Walter" last="Wodal">Walter Wodal</name><affiliation><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Orth/Donau, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Falkner, Falko G" sort="Falkner, Falko G" uniqKey="Falkner F" first="Falko G" last="Falkner">Falko G. Falkner</name></author><author><name sortKey="Kerschbaum, Astrid" sort="Kerschbaum, Astrid" uniqKey="Kerschbaum A" first="Astrid" last="Kerschbaum">Astrid Kerschbaum</name></author><author><name sortKey="Gaiswinkler, Claudia" sort="Gaiswinkler, Claudia" uniqKey="Gaiswinkler C" first="Claudia" last="Gaiswinkler">Claudia Gaiswinkler</name></author><author><name sortKey="Fritz, Richard" sort="Fritz, Richard" uniqKey="Fritz R" first="Richard" last="Fritz">Richard Fritz</name></author><author><name sortKey="Kiermayr, Stefan" sort="Kiermayr, Stefan" uniqKey="Kiermayr S" first="Stefan" last="Kiermayr">Stefan Kiermayr</name></author><author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Coulibaly, Sogue" sort="Coulibaly, Sogue" uniqKey="Coulibaly S" first="Sogue" last="Coulibaly">Sogue Coulibaly</name></author><author><name sortKey="Piskernik, Christina" sort="Piskernik, Christina" uniqKey="Piskernik C" first="Christina" last="Piskernik">Christina Piskernik</name></author><author><name sortKey="Hohenadl, Christine" sort="Hohenadl, Christine" uniqKey="Hohenadl C" first="Christine" last="Hohenadl">Christine Hohenadl</name></author><author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author><author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22580355</idno><idno type="pmid">22580355</idno><idno type="doi">10.1016/j.vaccine.2012.04.102</idno><idno type="wicri:Area/PubMed/Corpus">000C96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.</title><author><name sortKey="Wodal, Walter" sort="Wodal, Walter" uniqKey="Wodal W" first="Walter" last="Wodal">Walter Wodal</name><affiliation><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Orth/Donau, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Falkner, Falko G" sort="Falkner, Falko G" uniqKey="Falkner F" first="Falko G" last="Falkner">Falko G. Falkner</name></author><author><name sortKey="Kerschbaum, Astrid" sort="Kerschbaum, Astrid" uniqKey="Kerschbaum A" first="Astrid" last="Kerschbaum">Astrid Kerschbaum</name></author><author><name sortKey="Gaiswinkler, Claudia" sort="Gaiswinkler, Claudia" uniqKey="Gaiswinkler C" first="Claudia" last="Gaiswinkler">Claudia Gaiswinkler</name></author><author><name sortKey="Fritz, Richard" sort="Fritz, Richard" uniqKey="Fritz R" first="Richard" last="Fritz">Richard Fritz</name></author><author><name sortKey="Kiermayr, Stefan" sort="Kiermayr, Stefan" uniqKey="Kiermayr S" first="Stefan" last="Kiermayr">Stefan Kiermayr</name></author><author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Coulibaly, Sogue" sort="Coulibaly, Sogue" uniqKey="Coulibaly S" first="Sogue" last="Coulibaly">Sogue Coulibaly</name></author><author><name sortKey="Piskernik, Christina" sort="Piskernik, Christina" uniqKey="Piskernik C" first="Christina" last="Piskernik">Christina Piskernik</name></author><author><name sortKey="Hohenadl, Christine" sort="Hohenadl, Christine" uniqKey="Hohenadl C" first="Christine" last="Hohenadl">Christine Hohenadl</name></author><author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author><author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Guinea Pigs</term><term>Hemagglutination Inhibition Tests</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Influenza A Virus, H9N2 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neuraminidase (immunology)</term><term>Neutralization Tests</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Weight Loss</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H9N2 Subtype</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Guinea Pigs</term><term>Hemagglutination Inhibition Tests</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Weight Loss</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza viruses of subtype A/H9N2 are enzootic in poultry across Asia and the Middle East and are considered to have pandemic potential. The development of new vaccine manufacturing technologies is a cornerstone of influenza pandemic preparedness.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22580355</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2012</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>31</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.</ArticleTitle><Pagination><MedlinePgn>4625-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2012.04.102</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza viruses of subtype A/H9N2 are enzootic in poultry across Asia and the Middle East and are considered to have pandemic potential. The development of new vaccine manufacturing technologies is a cornerstone of influenza pandemic preparedness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A non-adjuvanted whole-virus H9N2 vaccine was developed using Vero cell culture manufacturing technology. The induction of hemagglutination inhibition (HI) and virus-neutralizing antibodies was assessed in CD1 mice and guinea pigs. A highly sensitive enzyme-linked lectin assay was used to investigate the induction of antibodies capable of inhibiting the enzymatic activity of the H9N2 neuraminidase. Protective efficacy against virus replication in the lung after challenge with the homologous virus was evaluated in BALB/c mice by a TCID(50) assay, and prevention of virus replication in the lung and associated pathology were evaluated by histology and immunohistochemistry. To investigate the ability of the vaccine to prevent severe disease, BALB/c mice were challenged with a highly virulent mouse-adapted H9N2 isolate which was generated by multiple lung-to-lung passage of wild-type virus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The vaccine elicited high titers of functional H9N2-specific HA antibodies in both mice and guinea pigs, as determined by HI and virus neutralization assays. High titer H9N2-specific neuraminidase inhibiting (NAi) antibodies were also induced in both species. Vaccinated mice were protected from lung virus replication in a dose-dependent manner after challenge with the homologous H9N2 virus. Immunohistochemical analyses confirmed the lack of virus replication in the lung and an associated substantial reduction in lung pathology. Dose-dependent protection from severe weight loss was also provided after challenge with the highly virulent mouse-adapted H9N2 virus.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The induction of high titers of H9N2-specific HI, virus-neutralizing and NAi antibodies and dose-dependent protection from virus replication and severe disease in animal models suggest that the Vero cell culture-derived whole-virus vaccine will provide an effective intervention in the event of a H9N2 pandemic situation.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wodal</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Orth/Donau, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falkner</LastName><ForeName>Falko G</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><LastName>Kerschbaum</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gaiswinkler</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fritz</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kiermayr</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Portsmouth</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Savidis-Dacho</LastName><ForeName>Helga</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Coulibaly</LastName><ForeName>Sogue</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Piskernik</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hohenadl</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>M Keith</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Kistner</LastName><ForeName>Otfried</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>P Noel</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Kreil</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053127" MajorTopicYN="N">Influenza A Virus, H9N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22580355</ArticleId><ArticleId IdType="pii">S0264-410X(12)00671-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2012.04.102</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22580355
|texte= A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22580355" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |